

Supplemental Table 3. Propensity score matching of baseline characteristics of patients divided into two groups by the median time to initiation of dapagliflozin after hospital admission (early initiation, i.e., by day 6, group E; late initiation, i.e., on day 7 or later, group L)

	Group E (n=28)	Group L (n=28)	P value
<i>Demographic variables</i>			
Age, median (IQR), y	70 (58, 78)	75 (62, 81)	0.37
Male sex, n (%)	20 (71.4)	20 (71.4)	1.00
Body mass index at admission, median (IQR), kg/m ²	27.7 (23.7, 33.0)	25.9 (22.8, 29.4)	0.27
Systolic BP at admission, mean±SD, mmHg	146±38	151±27	0.62
Type 2 diabetes, n (%)	12 (42.8)	10 (35.7)	0.58
Hypertension, n (%)	22 (78.5)	24 (85.7)	0.48
COPD, n (%)	2 (7.1)	3 (11.1)	0.60
Atrial fibrillation, n (%)	10 (35.7)	10 (35.7)	1.00
Ischemic etiology, n (%)	7 (25.0)	10 (35.7)	0.26
HFpEF, n (%)	10 (35.7)	9 (32.1)	0.77
NYHA class ≥III, n (%)	22 (78.5)	20 (71.4)	0.53
<i>Medications at discharge</i>			
ACE-I or ARB, n (%)	17 (60.7)	11 (39.2)	0.10
ARNI, n (%)	9 (32.1)	10 (35.7)	0.77
Beta-blocker, n (%)	25 (89.2)	25 (89.2)	1.00
Ivabradine, n (%)	2 (7.1)	2 (7.1)	1.00
Aldosterone antagonists, n (%)	21 (75.0)	16 (57.1)	0.15
Loop diuretic, n (%)	24 (85.7)	20 (74.0)	0.27
Tolvaptan, n (%)	11 (39.2)	9 (32.1)	0.57
DPP4-I, n (%)	8 (28.5)	4 (14.2)	0.18
<i>Laboratory variables at admission</i>			
Hemoglobin, mean±SD, g/dL	12.4±2.1	12.4±2.2	0.94
Hematocrit, mean±SD, %	38.8±6.1	38.8±6.4	0.88
Total bilirubin, median (IQR), mg/dL	0.84 (0.51, 1.27)	0.98 (0.64, 1.41)	0.30
AST, median (IQR), U/L	32 (24, 51)	27 (20, 38)	0.16
ALT, median (IQR), U/L	28 (20, 52)	19 (12, 35)	0.045
Albumin, median (IQR), g/dL	3.6 (3.3, 3.9)	3.5 (3.2, 3.9)	0.62
Sodium, median (IQR), mEq/L	141 (139, 142)	140 (138, 143)	0.67

BUN, median (IQR), mg/dL	17.8 (15.2, 27.6)	20.2 (15.1, 24.1)	0.92
Cr, median (IQR), mg/dL	1.05 (0.86, 1.35)	0.98 (0.82, 1.40)	0.65
eGFR, mean±SD, mL/min/1.73 m ²	51.0±18.2	52.5±17.0	0.76
NT pro-BNP, median (IQR), pg/mL	4206 (2178, 8222)	3454 (2050, 8546)	0.83
ePVS, median (IQR), dL/g	4.87 (3.89, 5.63)	4.92 (4.22, 6.22)	0.94
Laboratory variables at discharge			
Hemoglobin, median (IQR), g/dL	13.1 (12.1, 15.1)	11.9 (10.8, 14.4)	0.11
Hematocrit, median (IQR), %	40.8 (38.1, 47.5)	37.8 (35.0, 43.9)	0.12
Total bilirubin, median (IQR), mg/dL	0.66 (0.51, 1.00)	0.58 (0.41, 0.86)	0.15
AST, median (IQR), U/L	22 (18, 34)	22 (17, 33)	0.45
ALT, median (IQR), U/L	18 (14, 41)	25 (10, 38)	0.91
Albumin, mean±SD, g/dL	3.6±0.4	3.5±0.4	0.47
Sodium, median (IQR), mEq/L	140 (138, 142)	140 (138, 141)	0.98
BUN, median (IQR), mg/dL	21.7 (17.8, 30.9)	25.1 (17.7, 30.5)	0.87
Cr, median (IQR), mg/dL	1.11 (0.90, 1.40)	1.10 (0.87, 1.42)	0.77
eGFR, median (IQR), mL/min/1.73 m ²	44.8 (31.6, 58.7)	48.0 (34.7, 61.6)	0.72
NT pro-BNP, median (IQR), pg/mL	1150 (576, 2169)	960 (445, 1439)	0.71
ePVS, median (IQR), dL/g	4.46±1.09	4.87±1.33	0.21
ΔePVS, median (IQR), dL/g	0.51 (-0.03, 0.93)	0.33 (-0.36, 0.93)	0.30
Echocardiographic variables at admission			
LVDd, mean±SD, mm	58±8	54±11	0.18
LVEF, median (IQR), %	40 (31, 59)	40 (30, 51)	0.44
LAD, median (IQR), mm	45 (39, 51)	44 (40, 48)	0.94
E, mean±SD, m/s	94±29	90±28	0.61
E/e' ratio, median (IQR)	14.2 (11.9, 26.2)	18.0 (15.3, 20.8)	0.27
RVDD, mean±SD, mm	36±8	35±6	0.94
Moderate or severe TR, n (%)	8 (28.5)	9 (37.5)	0.49
TRPG, median (IQR), mmHg	29 (21, 37)	28 (21, 37)	0.80
Maximal IVC diameter, mean±SD, mm	18±5	18±5	0.93

For multiple comparisons, analysis of variance was used for symmetrical continuous variables, the Kruskal-Wallis test was used for asymmetric continuous variables, and the chi-squared test was used for categorical variables.

ACE-I, angiotensin converting enzyme inhibitor; ALT, alanine aminotransferase; ARB, angiotensin II receptor blocker; ARNI, angiotensin receptor-neprilysin inhibitor; AST, aspartate aminotransferase; BP, blood pressure; BUN, blood urea nitrogen; COPD, chronic obstructive pulmonary disease; Cr, creatinine; DPP4-I, dipeptidyl peptidase-4

inhibitor; E, peak early diastolic transmitral flow velocity; e', peak early diastolic mean mitral annular velocity; eGFR, estimated glomerular filtration rate; ePVS, estimated plasma volume status; HFpEF, heart failure with preserved ejection fraction; IQR, interquartile range; IVC, inferior vena cava; LAD, left atrial dimension; LVDd, left ventricular end-diastolic dimension; LVEF, left ventricular ejection fraction; NT pro-BNP, N-terminal pro-brain natriuretic peptide; NYHA, New York Heart Association; RVDd, right ventricular end-diastolic dimension; TR, tricuspid regurgitation; TRPG, tricuspid regurgitation pressure gradient.